SK Bioscience to export $51 bn flu vaccine to Thailand

The company will supply cell-cultured influenza vaccine Sky Cell Flu to Thailand's state-owned drug company GPO

SK Bioscience's flu vaccine Skycellflu
SK Bioscience's flu vaccine Skycellflu
Hyun-Ah Oh 1
Aug 21, 2023 (Gmt+09:00) 5hyun@hankyung.com
Bio & Pharma

SK Bioscience Co., the drug-making unit of South Korea’s SK Group, announced on Monday that it has signed a deal with Thailand's state-owned Government Pharmaceutical Organization (GPO) to supply the cell-cultured influenza vaccine "Sky Cell Flu" bulk amounting to 68 billion won ($50.7 million).

Following a memorandum of understanding (MOU) signed with GPO last month for local vaccine production and development infrastructure, SK Bioscience has now entered into an agreement to transfer the production technology of Sky Cell Flu.

As a result, the Korean company explained that it will supply the cell-cultured influenza vaccine bulk to GPO through the Thai company BGT.

SK Bioscience plans to collaborate with GPO in the medium to long term, promoting vaccine localization in Thailand and the ASEAN region, and building infrastructure to respond to new pandemics.

Write to Hyun-Ah Oh at 5hyun@hankyung.com
#SK Bioscience #SK Group #Government Pharmaceutical Organization #GPO #cell-cultured influenza vaccine #Sky Cell Flu

SK Bioscience buys 6.5 million Novavax shares for $83.4 million

SK Bioscience buys 6.5 million Novavax shares for $83.4 million

SK Bioscience CEO Ahn Jae-yong (left) and Novavax CEO John C. Jacobs pose for a photo after signing a strategic partnership agreement SK Bioscience Co., the drug-making unit of South Korea’s SK Group, said on Wednesday it has signed a deal to buy 6.5 million shares in US vaccine maker Nov

SK Bioscience, Thai’s GPO to jointly boost vaccine infrastructure

SK Bioscience, Thai’s GPO to jointly boost vaccine infrastructure

SK Bioscience Co., the drug-making unit of South Korea’s SK Group, announced on Wednesday that it has signed a memorandum of understanding (MOU) with Thailand's state-owned pharmaceutical company, Government Pharmaceutical Organization (GPO), aiming to bolster local vaccine production an

S.Korea's SK Bioscience to resume domestic flu vaccine output

S.Korea's SK Bioscience to resume domestic flu vaccine output

SK Bioscience's flu vaccine Skycellflu South Korea's SK Bioscience Co. will resume making domestic flu vaccines by year's end, two years after it stopped production to supply a vaccine for COVID-19. In a national vaccination project in which the government purchases all flu vaccines, the compan

SK Bioscience’s COVID-19 vaccine gets approval in UK

SK Bioscience’s COVID-19 vaccine gets approval in UK

SK Bioscience Co., the drug-making unit of South Korea’s SK Group, said on Monday that its domestic COVID-19 vaccine, SKYCovione, has received official marketing approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).The approval allows SKYCovione to be us

SK Bioscience to produce MSD’s new Ebola vaccine candidate

SK Bioscience to produce MSD’s new Ebola vaccine candidate

SK Bioscience Co., the drug-making unit of South Korea’s SK Group, announced on Monday that it has signed a contract with MSD, a global pharmaceutical company based in the United States, to start consignment production of next-generation Zaire Ebola vaccine candidate.MSD is currently dev